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Background: Antiretroviral treatment (ART) has substantially reduced morbidity and 
mortality for HIV patients. In South Africa, with the largest ART programme globally, 
attention is needed not only on the further expansion of ART coverage, but also on factors 
which undermine its effectiveness, such as alcohol use. 
Objective: Given the decentralised approach of nurse-initiated and -sustained ART in the 
South African primary health sector, it is important to document key aspects of alcohol use to 
be conveyed to HIV-positive individuals and those at risk for HIV. 
Method: This study comprised a narrative review of relevant literature.
Results: Alcohol acts through both behavioural and physiological pathways to impact on the 
acquisition, further transmission and then progression of HIV disease. Besides links to risky 
sex, alcohol undermines the immune system, raising susceptibility to contracting and then 
countering HIV and other infections. There are important drug interactions between alcohol 
and ART, or therapies for opportunistic infections and other co-morbidities. Moreover, alcohol 
undermines adherence to the medication which is essential for effective ART.
Conclusion: Primary healthcare clinic attendees need evidence-based information on the 
detrimental effects of alcohol consumption on HIV infection, which ensue throughout the 
clinical course of HIV. This spans the role of alcohol consumption as a risk factor for HIV 
infection, HIV replication in infected individuals, a person’s response to HIV infection and 
HIV treatment. Primary healthcare workers, especially nurses and HIV counsellors, require 
training in order to screen for and provide appropriate interventions for HIV-positive patients, 
those on treatment and treatment-naïve patients, who will benefit from reduced alcohol 
consumption or the cessation thereof. 
Introduction
Despite HIV prevalence reaching a plateau in South Africa, rates of new infection are still 
unacceptably high (Department of Health 2012:37). The Joint United Nations Programme on 
HIV/AIDS (UNAIDS) estimated that there were 5.6 million HIV-infected people living in South 
Africa in 2011. This figure, around 11% of the South African population (Doyle & Dorrington 
2011), makes up about 17% of the total global number of people living with HIV. Largely as 
a result of the expanded antiretroviral treatment (ART) programme, the biggest in the world 
(Shisana et al. 2009:viii), there has been a substantial reduction in AIDS-related mortality in South 
Africa. There were, however, still an estimated 194 000 HIV-related deaths in 2008, down from 
388 000 in 2003 (Actuarial Society 2011:1). 
South Africans are heavy drinkers, with amongst the highest per capita consumption rates for 
alcohol in the world, namely, 9.46 litres of pure alcohol per person annually (World Health 
Organization 2011:276). Alcohol consumption is frequent amongst HIV patients, with some 
studies showing rates of heavy drinking that are almost twice that of the general population 
(Galvan et al. 2002:179). Alcohol use disorders (AUDs) are common amongst HIV-infected 
persons, particularly hazardous alcohol consumption, resulting in decreased overall survival 
in this group (Braithwaite et al. 2007:462). Social and psychological aspects, such as the dual 
stigma of HIV infection and alcohol consumption, hinder health-seeking treatment for HIV and 
substance abuse (Morojele et al. 2010:10). 
HIV is not merely a biomedical phenomenon – the disease has a number of interacting 
socioeconomic, behavioural and psychological components. These, in turn, manifest as risk 
factors for HIV infection, acting through a myriad of pathways to HIV infection and then its 
consequences. In a conceptual framework comprising these components and pathways, Shuper 
et al. (2010:160) provide a tool for examining the associations between alcohol consumption 
and HIV infection. Unsafe sexual intercourse is an essential component for HIV infection. Sexual 
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transmission of HIV is contingent upon factors such as early 
sexual debut, the choice of sexual partner, frequency and 
type of sexual intercourse, the occurrence of sexual violence 
as well as the number and sequencing of sexual partners 
(Mah & Halperin 2010:16; Morojele et al. 2009:217; Shisana et al. 
2009:39). There is considerable interaction between each of 
the above factors and alcohol use. 
With ART, as with HIV prevention, cognisance needs to be 
taken of individual behaviours, as well as the social and 
structural forces that negate treatment outcomes. This is 
especially pertinent in the resource-poor South African public 
health sector (Delva, Pretorius & Temmerman 2009:638). 
Pandrea et al. (2010) examine the role of alcohol within 
the natural history of HIV infection, providing a useful 
framework for analysis. Alcohol consumption can be 
conceptualised as a pivot around which revolve four 
domains of the HIV epidemic (Pandrea et al. 2010:204). 
Each domain, with its specific topography and information, 
constitutes the roadmap needed to traverse this challenging 
health landscape. In the first, alcohol is linked with HIV 
acquisition. This encompasses the initial HIV infection, but 
also possible re-infection. HIV replication in the host, along 
with the host’s immune response, constitute the second 
and third domain, respectively. A fourth domain is ART 
and HIV care services, including access to care, HIV testing 
and counselling, the pharmacology of treatment drugs and 
adherence to medication. Alcohol consumption impacts 
negatively on all four domains, which are interlinked. This 
article discusses each domain, then sums up the key alcohol-
related information that health workers need to be aware of 
in order to discuss this information with patients receiving 
ART. The article draws on a narrative review of evidence on 
alcohol-HIV interactions, wherever possible citing systematic 
reviews on the topic, or empirical evidence where these are 
not available. 
Domain I: Alcohol as a risk factor 
for HIV transmission
A systematic review and meta-analysis of randomised 
studies by Rehm et al. (2012:51) found that alcohol use 
was an independent risk factor for the intention to engage 
in unprotected sex. They noted that an increase in blood 
alcohol content of 0.1 mg/mL leads to a 2.9% increase 
(95% CI = 2.0% – 3.9%) in the likelihood of engaging in 
unprotected sex. Empirical studies demonstrate how 
HIV and alcohol interconnect and how these interactions 
amplify negative health outcomes. For example, a study at 
a sexually-transmitted infection (STI) clinic in Cape Town 
(Simbayi et al. 2004:434) showed alcohol to be a major risk 
factor for STIs, with heavy drinking being linked with condom 
failure, a higher number of sexual partners and more STIs. 
A meta-analysis by Baliunas et al. (2010:162) concluded that 
alcohol consumption is associated with a 77% higher risk of 
incident HIV infection. Those drinking alcohol prior to, or 
at the time of, sexual relations were at an 87% increased risk 
of infection. For binge drinkers, the risk of HIV acquisition 
was twice that of non-binge drinkers. Another meta-analysis 
also demonstrated that alcohol use was associated with 
HIV infection in Africa (Fisher, Bang & Kapiga 2007:856). 
The pooled unadjusted odds ratio from 20 studies was 1.7 
(95% CI = 1.5–2.0). 
For drinkers, it is the quantity of alcohol per occasion, 
rather than the frequency of drinking, that predicts sexual 
risk-taking (Kalichman et al. 2007:146). The greater the 
quantity of alcohol consumed, the more likely the sexual risk 
behaviour. There are also gender differences with regard 
to alcohol use and sexual risks. Oftentimes, men drink and 
engage in higher-risk behaviour, whilst women’s risks may 
be associated with their male sex partners’ drinking. In the 
behavioural sphere, alcohol, besides its relationships with 
unprotected sex and other sexual risk behaviours, is linked 
to interpersonal violence, which can further increase HIV 
transmission (Schneider et al. 2007:665).
Domain II: HIV replication and 
Domain III: The immune system 
response
Clinical and experimental evidence demonstrate that both 
chronic and acute alcohol use impact negatively on the 
functioning of the human immune system (Molina et al. 2010). 
This impact is bi-directional, with alcohol both stimulating 
and reducing the host’s immune response. In an HIV-infected 
patient, alcohol may increase inflammation and immune 
response, thus raising the pool of HIV target cells at key 
transmission sites and throughout the body. This heightens 
HIV infectivity, for example, alcohol consumption may 
raise viral concentration in the semen and in the vagina, 
thereby enhancing the chances of onward HIV transmission 
(Pandrea et al. 2010:204). Even moderate alcohol ingestion 
enhances HIV replication in peripheral blood mononuclear 
cells in culture (Bagasra et al. 1996:550). By impacting on 
individual components of the immune system, however, 
alcohol consumption also suppresses the immune response, 
weakening the patient’s defences against HIV infection 
and opportunistic infections (both in resistance to them 
and in recovery from infection) (Pandrea et al. 2010:206).
Evidence that alcohol use hastens the progression of HIV 
disease is not conclusive (Baum et al. 2010:511). However, 
amongst those with HIV infection, the presence of alcohol 
use disorders was associated with increased plasma viral 
loads in five studies and decreased CD4 counts in four 
studies (Azar et al. 2010:185). For persons receiving ART, 
frequent alcohol use (≥ 2 drinks/day) resulted in a nearly 
three times higher risk of CD4 cell count decline to ≤ 200/μL 
compared with moderate alcohol use and abstention in one 
study (Baum et al. 2010:514). Moderate alcohol use (< 1 
drink/day over 6 months) did not, however, increase rate 
of CD4 decline to ≤ 200/μL compared with abstainers. 
For ART-naïve HIV-positive persons, frequent alcohol 
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use also increased their risk for CD4 decline to ≤ 200/μL. 
Furthermore (Baum et al. 2010:511) reported that CD4 decline 
was faster in frequent alcohol users who were not receiving 
ART than in those who were. Not all findings on the effects 
of alcohol on disease progression are consistent, however. 
A longitudinal study of American women with HIV by 
Ghebremichael et al. (2009:834) found no association between 
alcohol consumption and CD4 cell count, whether or not the 
participants were receiving ART. 
Domain IV: HIV treatment and care
The Annual Performance Plan 2012/13–2014/15 of the 
Department of Health states that the total number of patients 
receiving ART in 2009 was 1.1 million and the target for 
2014 is 2.5 million (Advocacy Aid 2012). Adam and Johnson 
(2009:661) estimated that of those South Africans receiving 
ART, almost 80% receive treatment in the public sector. 
This is notable, given that 79% of medical doctors work in 
the private sector in the country (Lawn & Kinney 2009:4). 
Notwithstanding the expansion of ART coverage, there 
remains a considerable unmet demand for ART, especially 
with the raising of the threshold for eligibility for ART from 
200 CD4 cells/μL to 350 cells/μL (Colvin et al. 2010:210; 
Health Systems Trust 2011:1). 
To facilitate treatment scale-up in the public sector, ART 
service delivery was decentralised in 2010, with the 
introduction of nurse-initiated ART as a strategy to secure 
the sustainability of services in the long run (Colvin et al. 
2010:210). In April 2012, there were 10 000 nurses certified 
to initiate ART in South Africa, a massive rise from the 250 
in February 2010 (Parliamentary Monitoring Group 2012). 
A randomised trial in urban clinics of Johannesburg and 
Cape Town demonstrated that nurse-managed ART was not 
inferior to doctor-managed ART (Sanne et al. 2010:33). Both 
groups had similar outcomes of viral suppression, adherence, 
toxicity and death. Moreover, nurses at primary care level are 
well placed to deal with the intersecting epidemics of HIV 
and alcohol abuse, ensuring effective treatment and patient 
management. 
Nurse-led ART and related interventions can also address 
the dual stigma surrounding HIV and alcohol use (Nyasulu 
et al. 2012:235). Stigma surrounding HIV and alcohol 
consumption may manifest in several ways: people may 
delay testing for HIV if they have a drinking problem or 
may not attend scheduled follow-up visits if inebriated or 
recovering from recent alcohol use. Also, patients who abuse 
alcohol and suspect they may be HIV-positive may elect 
not to attend HIV clinics based on the mistaken belief that 
ART will be withheld because of their alcohol consumption. 
In one study, men reported self-imposed delays in ART 
enrolment as a result of alcohol use (Fitzgerald, Collumbien 
& Hosegood 2010:355). Alcohol consumption reduces ART 
efficacy through several mechanisms. Besides impacting 
on adherence to ARV drugs, effects include adverse drug 
reactions (ADRs), drug–drug interactions, direct liver 
toxicity and other physiological and biological aberrations, 
with the result that ARVs are processed improperly, with 
diminished effectiveness. Also, it is important that ART is 
taken correctly, as this reduces further HIV transmission by 
reducing levels of infectivity.
Adherence to antiretroviral medication
ART works suboptimally in a non-adherent patient; 
resistance to antiretroviral (ARV) drugs can develop, HIV 
viral load increases and CD4 counts decline, with concomitant 
poor health (NAM 2009). Furthermore, extended treatment 
interruptions have a greater impact on treatment failure than 
occasional missed ARV doses (Kalichman et al. 2012a:512). 
Substantial and consistent associations have been found 
between alcohol use and ARV non-adherence. Alcohol 
drinkers are up to 50% – 60% less likely to be classified as 
adherent to HIV medications, compared with abstainers. 
The largest effect was for problem drinkers, who were 
47% less likely to be adherent compared with those who 
drank relatively less (Hendershot et al. 2009:180). A finding 
by Braithwaite et al. (2008:1651), which is of relevance to 
HIV-positive individuals, is that hazardous episodic drinking 
rather than high average daily drinking was associated with 
non-adherence.
Drinking alcohol impacts on cognitive functioning, leading 
to missed doses of drugs. However, a study by Sankar 
et al. (2007:195) demonstrated non-compliance with ARV 
medication as being not the result of being inebriated, but 
rather a deliberate decision not to drink alcohol and take 
ARV medication simultaneously. A prospective study in the 
United States found a positive relationship between the belief 
that mixing alcohol and ART is toxic (interactive toxicity 
beliefs) and intentional non-adherence. During drinking 
episodes, people thus often intentionally interrupt ART based 
on these beliefs (Kalichman et al. 2012b:399). 
Adverse drug reactions 
An ADR caused by alcohol is defined as the clinical 
consequence of alcohol intake before, concomitant with or 
immediately after taking ARV drugs. Both alcohol and ARVs 
are metabolised by CYP450 enzymes. ARVs may inhibit or 
induce the enzymes within this system. The non-nucleoside 
reverse transcriptase inhibitor (NNRTI), efavirenz, for 
example, induces these enzymes. This hastens the drug-
clearing processes in the liver and other organs, such as 
the stomach. This may cause HIV drugs to be cleared too 
quickly, undermining their effectiveness and facilitating 
viral resistance. It should be noted that not just HIV drugs, 
but several other medications may be cleared faster. On the 
other hand, some protease inhibitor drugs (PIs), particularly 
ritonavir, inhibit CYP450 enzyme function (BioPortfolio 
2010). This slows down how the liver clears medications, 
leading to higher concentrations of these medications, which 
often reach toxic levels (Potochnic 2002). 
The pattern of alcohol consumption plays a role here too, 
determining the effect on liver enzymes. Acute ingestion of 
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alcohol with ART results in the inhibition of the liver enzymes 
(CYP2E1 and 3A4). However, chronic alcohol ingestion leads 
to enzyme induction, which may result in subtherapeutic 
levels of PIs and NNRTIs (Pujol 2003).
Organ damage: The liver 
Alcohol use, in particular hazardous drinking, can lead to 
liver pathology (Szabo & Mandrekar 2010). Similarly, some 
ARV drugs, used over an extended period, may induce liver 
damage. The liver metabolises both alcohol and ARVs; and 
a diseased liver can process neither effectively. Hepatitis 
viruses and alcohol act synergistically, hastening the 
progression of liver disease (Neuman et al. 2012:4). 
Wyles and Gerber (2005:181) conclude that liver dysfunction 
has a considerable impact on PI metabolism, but, on the whole, 
processing of NNRTIs and nucleoside reverse transcriptase 
inhibitors (NRTIs) are affected minimally. Liver toxicity is a 
common side effect with the use of nevirapine or lopinavir/
ritonavir. Liver problems only occur rarely with efavirenz. 
The altered drug metabolism in people with liver damage 
can be managed by adjusting drug doses (Highleyman 2005).
The South African Medicines Formulary (Rossiter 2012) 
suggests prescribing stavudine or lopinavir/ritinovir with 
caution in patients with a history of hepatic disease. For 
lamivudine and nevirapine, the caution is liver impairment, 
whilst for didanosine, the caution is alcoholism. People 
taking the latter drug should avoid all kinds of drinking, 
because of the potential for increased risk of pancreatitis 
(Manfredi & Calza 2008:99). 
Co-morbid conditions and effects on other 
systems
Alcohol also has the potential to impact negatively on 
medicines used to treat HIV-related opportunistic infections, 
specifically those for treating tuberculosis (TB), hepatitis 
B virus and hepatitis C (Neuman, Monteiro & Rehm 
2006:1395). For example, alcohol reduces the efficacy of 
rifampicin, which is used to treat HIV/TB co-infection 
(Moreno et al. 2001:1185). ARVs, furthermore, counteract 
some pharmacotherapies to treat alcoholism, for example, 
lopinavir and/or ritonavir is contraindicated with the use of 
disulfiram (Cvetkovic & Goa 2003:769). 
Some ARVs raise blood lipids levels (such as cholesterol 
and triglycerides) and heavy alcohol consumption may 
exacerbate this (Míguez-Burbano, Lewis & Malow 2009b:176). 
Resulting dyslipidaemias enhance risk for cardiovascular 
disease, which is also associated with alcohol use. Also, 
peripheral neuropathies from dideoxyinosine (LeLacheur & 
Simon 1991:538) may be worsened by the neurotoxic effects 
of alcohol.
Alcohol use for persons living with HIV
There are differing views regarding whether moderate use 
of alcohol is harmful for persons living with HIV (PLWH), 
although there is widespread lay and medical professional 
agreement that use of alcohol and HIV treatment do not 
mix well (Kalichman et al. 2009:449). Bryant (2006:1465), for 
example, states that current research supports the conclusion 
that ‘perhaps no level of alcohol consumption is “safe” once 
individuals are infected with HIV’. On the other hand, a 
British publication maintains that there is no evidence that 
moderate alcohol consumption is harmful for HIV-infected 
people (Carter 2011). Alcohol consumption may help allay 
anxiety and the moderate consumption of alcohol may serve 
as a coping mechanism for individuals struggling to come 
to terms with the disease. Furthermore, certain alcoholic 
beverages such as red wine are considered to have health 
benefits. A glass of wine can serve as an appetite stimulant, 
which may benefit some HIV-positive individuals with 
appetite loss. Conigliaro et al. (2006:S1) state that the quantity 
and frequency of alcohol consumption that constitutes 
a measurable harm for HIV patients has not yet been 
established, but is likely to be less than that recommended 
for the general population. Ellison (2002:6) observes that, 
unlike other populations, it has not been demonstrated that 
alcohol has beneficial health effects for HIV-positive people. 
Notably, in HIV-infected individuals, the threshold level of 
cognitive impairment that affected non-adherence occurred 
at moderate, not at high, levels of alcohol consumption. This 
lower tolerance level results from the effect of the virus, 
ART and, possibly, ageing (Braithwaite et al. 2008:1651). 
Importantly, it is ill-advised for an individual to reduce or 
suddenly discontinue alcohol consumption after a long 
period of excessive intake as this might precipitate alcohol 
withdrawal syndrome.
Of note, eliciting information from HIV patients about 
their alcohol consumption is important, as alcohol abuse 
or dependence, even in the past, may be an important 
determinant of the best HIV treatment approach for a patient 
(Conigliaro et al. 2006:S2). For people with HIV infection, 
not only the amount of alcohol consumed and the patterns 
of alcohol use are relevant to HIV disease progression, but 
also perhaps the type of liquor consumed (Míguez-Burbano 
et al. 2009a:366). Patients who drank spirits that included 
gin, vodka and whiskey, as opposed to consuming wine and 
beer, had poorer viro-immune outcomes of ART.
Discussion
Heavy, chronic alcohol consumption alters the physiology 
and biology of every cell in the human body, including the 
immune system. Despite the well-documented negative 
effects of alcohol, legislating commensurate alcohol 
regulation has proven difficult due to powerful economic 
and social counterforces in play, particularly in South Africa 
(Parry 2010:1340). Effective interventions to counter the 
adverse health outcomes of alcohol use are, of necessity, 
intersectoral and multilevel. The health sector primarily 
deals with the fallout from hazardous and harmful alcohol 
use. Most interventions that could target the nexus of alcohol 
use and unsafe sex lie outside the health sphere. These 
interventions have been described widely, are considered to 
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be effective and need to be applied as a matter of urgency 
(Parry, Rehm & Morojele 2010:86). 
In the health sector, alcohol consumption is considered 
a modifiable health risk, amenable to screening and 
interventions. Alcohol use varies considerably amongst 
drinkers and can be categorised by the number of drinks 
consumed; or whether someone is a binge drinker or not; or 
by the impact of alcohol consumption on health in terms of 
responsible, hazardous or harmful use. The National Institute 
on Alcohol Abuse (NIAAA) defines moderate drinking as 
no more than four drinks on any single day and under 14 
drinks per week for men. For women, the recommendation 
is no more than three drinks on any single day and less than 
seven drinks per week (NIAAA 2012a). Hazardous drinking 
is defined as drinking above these recommended limits and 
increases one’s vulnerability to illness, injury, and social or 
legal problems (NIAAA 2012b). 
The AUDIT tool screens for people who will benefit from 
reducing or ceasing to drink alcohol (Babor et al. 2001:4). This 
tool is used, commonly, to identify the severity of alcohol 
problems. It is designed for use in primary healthcare 
settings, with HIV counsellors and nurses considered to be 
appropriate screening personnel (Babor et al. 2001:9). The 
AUDIT comprises 10 questions, which are then scored. Based 
on these scores, patients are stratified from low-risk alcohol 
consumption to alcohol dependency (Babor et al. 2001:19). 
Low-risk drinkers with an AUDIT score of 0 to 7 require 
only alcohol education; a score of 8 to 15 necessitates simple 
advice given to reduce hazardous drinking; scores from 16 to 
19 suggest harmful drinking and should prompt provision 
of counselling with Brief Interventions, as well as continued 
monitoring; and, finally, a score of 20 or more requires referral 
to a specialist for full diagnostic evaluation and treatment for 
alcohol dependence (Babor et al. 2001:20). In addition, past 
alcohol use, as determined from the final two questions of the 
AUDIT, indicates a need for monitoring, despite the fact that 
these patients do not currently consume alcohol (Babor et al. 
2001:19). Furthermore, these guidelines should be considered 
together with clinical judgement of the patient’s HIV disease 
stage, family history of alcohol problems and the perceived 
honesty of the patient in responding to the AUDIT questions 
(Babor et al. 2001:20). 
Brief Interventions are effective for addressing hazardous 
and harmful drinking, as are more specialised addiction 
services for those with alcohol dependence (Kaner et al. 
2009:301). Typically, Brief Interventions entail one to four 
short one-on-one counselling sessions. These interventions 
are delivered via a specific technique of interviewing, namely, 
motivational interviewing. Patients are encouraged to think 
about making changes relating to their alcohol consumption 
behaviours. At a minimum, it seeks to equip them with skills 
to apply in consuming alcoholic beverages in a safer way.
Two studies demonstrated the effectiveness of group 
interventions in resource-scarce settings. One by Wechsberg 
et al. (2008:130) utilised a brief behavioural intervention 
for a group of high-risk women in the Cape Province, to 
address HIV issues, substance use and risky sexual practices. 
Another, by Papas et al. (2010:669), applied a cognitive 
behavioural method to reduce alcohol use amongst HIV-
infected outpatients in Kenya. 
A key problem for South African health workers at the 
interface of the dual HIV and alcohol epidemics is the lack 
of integration of addiction centres and HIV clinics within 
primary facilities (Parry et al. 2010:90). Information on where 
to refer patients with identified alcohol abuse problems is 
often unavailable at primary care level. Conversely, staff 
working at drug and alcohol treatment centres should 
include HIV prevention, treatment and onward referrals in 
their scope of work.
Patients with alcohol problems also require screening 
for alcohol-related HIV risk. This includes ascertaining 
drinking patterns around sexual intercourse and correct 
condom usage, as well as choice and number of sexual 
partners when drinking. Parry et al. (2010:90) suggest staff 
need to be cross-trained in HIV and alcohol problems in 
order to ensure sufficient capacity. A hospital-based study 
in HIV care centres in New York City also found that health 
providers routinely implemented more alcohol intervention 
components if they had greater exposure to information 
on the effect of alcohol on HIV (Strauss et al. 2009:211). A 
study by Korthuis et al. (2008:301), looking at HIV-infected 
American adults, found that patient-provider discussions 
on substance use led to increased utilisation of addiction 
services. Treatment for substance abuse is linked to reduced 
HIV-risk behaviour and improved HIV prognosis (increased 
ARV drug adherence in men, decreased hospitalisation and 
increased receipt of primary care) (Korthuis et al. 2008:295). 
 
Other studies had less assuring findings. Bryant (2006:1486) 
found that American medical care providers are often 
uninformed about the interactions of alcohol with HIV 
progression and treatment, hence do not take this into 
account when making clinical decisions. A qualitative study 
of a general patient population in America noted that many 
providers were uncomfortable about or avoided discussing 
substance abuse with patients, or gave vague limited advice 
(McCormick et al. 2006:966). A later study in American HIV 
clinics (Korthuis et al. 2011:841) found that the quality of 
patient-provider communication was worse for HIV-
infected patients with unhealthy alcohol use, compared 
with non-users. Similarly, a cohort study amongst HIV-
positive American veterans (Conigliaro et al. 2003:523) 
demonstrated that health providers usually missed alcohol 
problems in patients with less severe HIV staging or those 
lacking evidence of liver disease. 
Encouragingly, a South African study in 2005–2006 
(Morojele et al. 2010:1) showed that, contrary to expectations, 
many HIV care and treatment programmes already consider 
the role of alcohol consumption and HIV in their approach to 
treatment. However, lack of resources, information and skills 
hamper the management of HIV clients with harmful drinking 
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practices. Given the scaling up of the ART rollout, with the 
twin goals of both high ART coverage and optimal treatment 
outcomes (Kapp 2009), ineffective ART management at 
primary healthcare level would be counterproductive in 
terms of health outcomes, wasted resources and the adverse 
effects on staff morale. Allocation of resources in South Africa 
for the additional training of nurses to deal with substance 
abuse amongst HIV-infected people attending HIV, STI and 
TB clinics warrants very high priority.
Recommendations for patient care
To minimise the development of hepatic toxicity and 
retard HIV disease progression, health providers should 
offer alcohol screening and counselling to HIV-infected 
patients, as part of routine patient care (Parry et al. 2010:91). 
A minimum requirement is that health workers broach 
the subject of alcohol use with HIV-positive patients and 
encourage alcohol reduction and maintenance of ART. Health 
workers, particularly at primary care level for HIV, need to 
make patients aware of the detrimental effects of alcohol 
consumption. Such discussions, both for treatment-naïve HIV 
patients and those receiving ART, should encompass alcohol 
use and sexual risk behaviour. This includes emphasising 
the juncture between alcohol use and sexual violence, which 
often involves unsafe sex. Patients need information about 
the fact that alcohol consumption increases viral replication, 
that is, higher levels of HIV in the body, leading to accelerated 
disease progression. Alcohol has a negative effect on the 
immune system, increasing susceptibility to opportunistic 
infections. 
Patients require information on how alcohol interacts with 
ARVs and other medications used to treat opportunist 
infections, such as TB. They should not stop taking their 
ARVs if they have a binge drinking episode. Stopping and 
starting ART is not a viable treatment option. Damage 
caused by ART non-adherence likely outweighs that of 
alcohol and ARV drug interactions (Kalichman et al. 2012b). 
A conservative recommendation is that alcohol should be 
avoided altogether, both prior to commencing HIV treatment 
and, thereafter, once on ART. This is particularly valid for 
people with viral hepatitis co-infection or who are at risk 
of liver toxicity from their ART medications. For patients 
on ART, any alcohol consumption is likely inadvisable. 
Nonetheless, for HIV-positive patients who consume alcohol 
and need treatment, ART should be initiated and continued, 
together with efforts to taper off their drinking.
Conclusion
The issue of scarce resources and structural problems 
within the health sector in South Africa aside, it is of vital 
importance for primary healthcare workers to be sensitised 
to and build knowledge of the interconnectedness of HIV 
and alcohol use. Nurses need to be trained to provide 
guidance on the interactions between alcohol consumption 
and HIV across each domain described above. Furthermore, 
these health workers need to confront the psychological 
barriers patients may have, with dual stigmas from alcohol 
consumption and HIV infection.
The overall cumulative health burden of HIV will increase 
even further without proactive and effective efforts to 
address problem drinking in South Africa. In the absence of 
such interventions, the prevailing levels of alcohol use will 
hinder further progress in reducing new HIV infections and 
will further amplify the overall burden of HIV on society in 
general and on the healthcare system in particular. 
Acknowledgements 
The preparation of this manuscript was funded by the US 
President’s Emergency Fund for AIDS Relief (PEPFAR) 
through the US Centers of Disease Control and Prevention 
(CDC) (PO S-SF750-06-M-0781). Its contents are solely the 
responsibility of the authors and do not necessarily represent 
the official views of CDC or PEPFAR.
We would like to thank Professor Marc Blockman, Division 
of Pharmacology, University of Cape Town for his comments 
on the section: Adverse drug reactions. 
Competing interests 
The authors declare that they have no financial or personal 
relationship which may have inappropriately influenced 
them in writing this article. 
Authors’ contributions
M.S. (Medical Research Council) conceptualised, researched, 
did literature searches for and wrote the article. M.C. 
(University of Witwatersrand) and C.P. (Medical Research 
Council) assisted with the writing of the article, information 
sources as well as editing, in particular the structuring of the 
article. M.T. (University Ghent) and O.D. (University Ghent) 
read the final version and provided edits and comments.
References
Actuarial Society, 2011, AIDS Committee Newsletter, September, viewed 12 March 
2012, from aids.actuarialsociety.org.za/.../buildfile.asp? 
Adam, M.A. & Johnson, L.F., 2009, ‘Estimation of adult antiretroviral treatment 
coverage in South Africa’, South African Medical Journal 99(9), 661–667.
Advocacy Aid, 2012, Annual performance plan 2012/13–2014/15, viewed 10 
June 2014, from http://www.advocacyaid.com/index.php/health-care/98-
department-of-health-publishes-annual-performance-plan 
Azar, M.M., Springer, S.A., Meyer, J.P. & Altice, F.L., 2010, ‘A systematic review of 
the impact of alcohol use disorders on HIV treatment outcomes, adherence to 
antiretroviral therapy and health care utilization’, Drug and Alcohol Dependence 
112(3), 178–193.
Babor, T.F., Higgins-Biddle, J.C., Saunders J.B. & Monteiro, M.G., 2001, AUDIT: The 
Alcohol Use Disorders Identification Test. Guidelines for use in primary care, 
WHO/MSD/MSB/01.6a, 2nd edn., Department of Mental Health and Substance 
Dependence, World Health Organization, viewed 14 March 2012, from http://
whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf
Bagasra, O., Bachman, S.E., Jew, L., Tawadros, R., Cater, J., Boden, G. et al., 1996, 
‘Increased human immunodeficiency virus type 1 replication in human peripheral 
blood mononuclear cells induced by ethanol: Potential immunopathogenic 
mechanisms’, Journal of Infectious Diseases 173(3), 550–558. http://dx.doi.
org/10.1093/infdis/173.3.550
Baliunas, D., Rehm, J., Irving, H. & Shuper, P., 2010, ‘Alcohol consumption and risk of 
incident human immunodeficiency virus infection: A meta-analysis’, International 
Journal of Public Health 55(3), 159–166. http://dx.doi.org/10.1007/s00038-009-
0095-x
Baum, M.K., Rafie, C., Lai, S., Sales, S., Page, J.B. & Campa, A., 2010, ‘Alcohol use 
accelerates HIV disease progression’, AIDS Research and Human Retroviruses 
26(5), 511–518. http://dx.doi.org/10.1089/aid.2009.0211
Original Research
doi:10.4102/curationis.v37i1.1137http://www.curationis.org.za
Page 7 of 8
BioPortfolio, 2010, Interaction of alcohol and highly active antiretroviral therapy 
(HAART) in HIV/AIDS and HIV/AIDS with hepatitis C virus (HCV) co-infection, 
viewed 12 April 2012, from http://www.bioportfolio.com/resources/trial/78003/
Interaction-Of-Alcohol-And-Highly-Active-Antiretroviral-Therapy-haart-In-Hiv-
aids.html 
Braithwaite, R.S., Conigliaro, J., McGinnis, K.A., Maisto, S.A., Bryant, K. & Justice, 
A.C., 2008, ‘Adjusting alcohol quantity for mean consumption and intoxication 
threshold improves prediction of nonadherence in HIV patients and HIV-negative 
controls’, Alcoholism, Clinical and Experimental Research 32(9), 1645–1651. 
http://dx.doi.org/10.1111/j.1530-0277.2008.00732.x
Braithwaite, R.S., Conigliaro, J., Roberts, M.S., Shechter, S., Schaefer, A., 
McGinnis, K. et al., 2007, Estimating the impact of alcohol consumption 
on survival for HIV+ individuals. AIDS Care, 19(4), 459−466. http://dx.doi.
org/10.1080/09540120601095734
Bryant, K.J., 2006, ‘Expanding research on the role of alcohol consumption and related 
risks in the prevention and treatment of HIV/AIDS’, Substance Use & Misuse 
41(10), 1465–1507. http://dx.doi.org/10.1080/10826080600846250
Carter, M., 2011, Alcohol, viewed 10 March 2012, from http://www.aidsmap.com/
Alcohol/page/1045082/ 
Colvin, C.J., Fairall, L., Lewin, S., Georgeu, D., Zwarenstein, M., Bachmann, M.O. et 
al., 2010, ‘Expanding access to ART in South Africa: The role of nurse-initiated 
treatment’, South African Medical Journal 100(4), 210–212.
Conigliaro, J., Gordon, A.J., McGinnis, K.A., Rabeneck, L, Justice, A.C.; Veterans 
Aging Cohort 3-Site Study, 2003, ‘How harmful is hazardous alcohol use and 
abuse in HIV infection: Do health care providers know who is at risk?’, Journal 
of Acquired Immune Deficiency Syndromes 33(4), 521–525. http://dx.doi.
org/10.1097/00126334-200308010-00014
Conigliaro, J., Justice, A.C., Gordon, A.J., Bryant, K.; VACS Alcohol & Behavior Change 
Research Group, 2006, ‘Role of alcohol in determining human immunodeficiency 
virus (HIV)-relevant outcomes: A conceptual model to guide the implementation 
of evidence-based interventions into practice’, Medical Care 44(8 Suppl 2), S1–S6. 
http://dx.doi.org/10.1097/01.mlr.0000223659.36369.cf
Cvetkovic, R.S. & Goa, K.L., 2003, ‘Lopinavir/ritonavir: A review of its use in 
the management of HIV infection’, Drugs 63(8), 769–802. http://dx.doi.
org/10.2165/00003495-200363080-00004
Delva, W., Pretorius, C. & Temmerman M., 2009, ‘Is scaling up enough to curb the 
HIV epidemic in southern Africa?’, South African Medical Journal 99(9), 638–639.
Department of Health, 2012, Annual Report 2012/2013, viewed 10 June 2014, from 
http://africacheck.org/wp-content/uploads/2014/02/131016dohrreport.pdf 
Doyle, P. & Dorrington, R., 2011, Expansion of ARV programme in SA slows AIDS 
mortality rate, viewed 08 June 2014, from http://sareporter.com/index.
php?option=com_content&task=view&id=1946&Itemid=46
Ellison, R.C., 2002, ‘Balancing the risks and benefits of moderate drinking’, 
Annals of the New York Academy of Sciences 957, 1–6. http://dx.doi.
org/10.1111/j.1749-6632.2002.tb02900.x
Fisher, J.C., Bang, H. & Kapiga, S.H., 2007, ‘The association between HIV infection 
and alcohol use: A systematic review and meta-analysis of African studies’, 
Sexually Transmitted Diseases 34(11), 856–863. http://dx.doi.org/10.1097/
OLQ.0b013e318067b4fd
Fitzgerald, M., Collumbien, M. & Hosegood, V., 2010, ‘“No one can ask me ‘Why do you 
take that stuff?’”: Men’s experiences of antiretroviral treatment in South Africa’, 
AIDS Care 22(3), 355–360. http://dx.doi.org/10.1080/09540120903111536
Galvan, F.H., Bing, E.G., Fleishman, J.A., London, A.S., Caetano, R., Burnam, M.A. et al., 
2002, ‘The prevalence of alcohol consumption and heavy drinking among people 
with HIV in the United States: Results from the HIV Cost and Services Utilization 
Study’, Journal of Studies on Alcohol 63(2), 179–186.
Ghebremichael, M., Paintsil, E., Ickovics, J.R., Vlahov, D., Schuman, P., Boland, R. et al., 
2009, ‘Longitudinal association of alcohol use with HIV disease progression and 
psychological health of women with HIV’, AIDS Care 21(7), 834–841. http://dx.doi.
org/10.1080/09540120802537864
Health Systems Trust, 2011, South Africa: Govt moves to earlier HIV treatment, viewed 
15 March 2012, from http://www.hst.org.za/news/south-africa-govt-moves-
earlier-hiv-treatment 
Hendershot, C.S., Stoner, S.A., Pantalone, D.W. & Simoni, J.M., 2009, ‘Alcohol use 
and antiretroviral adherence: Review and meta-analysis’, Journal of Acquired 
Immune Deficiency Syndromes 52(2), 180–202. http://dx.doi.org/10.1097/
QAI.0b013e3181b18b6e
Highleyman, L., 2005, Drug interactions and anti-HIV therapy, viewed 12 April 2012, 
from http://www.thebody.com/content/art2579.html 
Kalichman, S.C., Amaral, C.M., White, D., Swetsze, C., Kalichman, M.O., Cherry, C. 
et al., 2012a, ‘Alcohol and adherence to antiretroviral medications: interactive 
toxicity beliefs among people living with HIV’, Journal of the Association of Nurses 
in AIDS Care 23(6), 511–520. http://dx.doi.org/10.1016/j.jana.2011.11.005
Kalichman, S.C., Amaral, C.M., White, D., Swetsze, C., Pope, H., Kalichman, M.O. et 
al., 2009, ‘Prevalence and clinical implications of interactive toxicity beliefs 
regarding mixing alcohol and antiretroviral therapies among people living with 
HIV/AIDS’, AIDS Patient Care and STDs 23(6), 449–454. http://dx.doi.org/10.1089/
apc.2008.0184
Kalichman, S.C., Grebler, T., Amaral, C.M., McNerey, M., White, D., Kalichman, M.O. et 
al., 2012b, ‘Intentional non-adherence to medications among HIV positive alcohol 
drinkers: Prospective study of interactive toxicity beliefs’, Journal of General 
Internal Medicine 28(3), 399–405. http://dx.doi.org/10.1007/s11606-012-2231-1
Kalichman, S.C., Simbayi, L.C., Kaufman, M., Cain, D. & Jooste, S., 2007, ‘Alcohol use 
and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical 
findings’, Prevention Science 8(2), 141–151. http://dx.doi.org/10.1007/s11121-
006-0061-2
Kaner, E.F., Beyer, F., Dickinson, H.O., Pienaar, E., Campbell, F., Schlesinger, C. et al., 
2009, ‘Effectiveness of brief alcohol interventions in primary care populations’, 
Drug and Alcohol Review 28(3), 301–323. http://dx.doi.org/10.1111/j.1465-
3362.2009.00071.x
Kapp, C., 2009, ‘Aaron Motsoaledi: South African Minister of Health’, Lancet 
374(9692), 776. http://dx.doi.org/10.1016/S0140-6736(09)61580-4
Korthuis, P.T., Josephs, J.S., Fleishman, J.A., Hellinger, J., Himelhoch, S., Chander, G. 
et al., 2008, ‘Substance abuse treatment in human immunodeficiency virus: the 
role of patient-provider discussions’, Journal of Substance Abuse Treatment 35(3), 
294–303. http://dx.doi.org/10.1016/j.jsat.2007.11.005
Korthuis, P.T., Saha, S., Chander, G., McCarty, D., Moore, R.D., Cohn, J.A. et al., 2011, 
‘Substance use and the quality of patient-provider communication in HIV clinics’, 
AIDS and Behavior 15(4), 832–841. http://dx.doi.org/10.1007/s10461-010-9779-8
Lawn, J.E. & Kinney, M.V., 2009, ‘Health in South Africa. An executive summary for The 
Lancet Series’, The Lancet 347, 1–8.
LeLacheur, S.F. & Simon, G.L., 1991, ‘Exacerbation of dideoxycytidine-induced 
neuropathy with dideoxyinosine’, Journal of Acquired Immune Deficiency 
Syndromes 4(5), 538–539.
Mah, T.L. & Halperin, D.T., 2010, ‘Concurrent sexual partnerships and the HIV 
epidemics in Africa: Evidence to move forward’, AIDS and Behavior 14(1), 11–16. 
http://dx.doi.org/10.1007/s10461-008-9433-x
Manfredi, R. & Calza, L., 2008, ‘HIV infection and the pancreas: Risk factors and 
potential management guidelines’, International Journal of STD & AIDS 19(2), 
99–105. http://dx.doi.org/10.1258/ijsa.2007.007076
McCormick, K.A., Cochran, N.E., Back, A.L., Merrill, J.O., Williams, E.C. & Bradley, K.A., 
2006, ‘How primary care providers talk to patients about alcohol: a qualitative 
study’, Journal of General Internal Medicine 21(9), 966–972. http://dx.doi.
org/10.1007/BF02743146
Míguez-Burbano, M.J., Lewis, J.E., Fishman, J., Asthana, D. & Malow, R. M., 2009a, 
‘The influence of different types of alcoholic beverages on disrupting highly active 
antiretroviral treatment (HAART) outcome’, Alcohol and Alcoholism 44(4), 366–
371. http://dx.doi.org/10.1093/alcalc/agp024
Míguez-Burbano, M.J., Lewis, J.E. & Malow, R., 2009b, ‘Alcohol and race/ethnicity 
elicit different changes in lipid profiles in HIV-infected individuals receiving highly 
active antiretroviral therapy’, Journal of the Association of Nurses in AIDS Care 
20(3), 176–183. http://dx.doi.org/10.1016/j.jana.2009.02.004
Molina, P.E., Happel, K.I., Zhang, P., Kolls, J.K. & Nelson, S., 2010, Focus on: Alcohol and 
the immune system, viewed 29 February 2012, from http://pubs.niaaa.nih.gov/
publications/arh40/97-108.htm 
Moreno, S., Podzamczer, D., Blázquez, R., Iribarren, J.A., Ferrer, E., Reparaz, J. et al., 
2001, ‘Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral 
efficacy of the concomitant use of ritonavir and rifampin’, AIDS 15(9), 1185–1187. 
http://dx.doi.org/10.1097/00002030-200106150-00018
Morojele, N.K., Kachieng’a, M.A., Mokoko, E., Nkoko, M.A., Parry, C.D., Nkowane, A.M. 
et al., 2009, ‘Alcohol use and sexual behaviour among risky drinkers and bar and 
shebeen patrons in Gauteng province, South Africa’, Social Science & Medicine 
62(1), 217–227. http://dx.doi.org/10.1016/j.socscimed.2005.05.031
Morojele, N.K., Pithey, A.L., Kekwaletswe, C.T., Joubert-Wallis, M., Pule, M. & Parry, 
C.D.H., 2010, ‘South African health care providers’ recognition of the links 
between alcohol and HIV in their daily practice: A pilot study’, African Journal of 
Drug and Alcohol Studies 9(1), 1–14. http://dx.doi.org/10.4314/ajdas.v9i1.61753
NAM, 2009, Adherence, viewed 10 March 2012, from http://aidsprogramme.ukzn.
ac.za/Libraries/HIV_Treatment/adherence.sflb.ashx 
Neuman, M.G., Monteiro, M. & Rehm, J., 2006, ‘Drug interactions between 
psychoactive substances and antiretroviral therapy in individuals infected 
with human immunodeficiency and hepatitis viruses’, Substance Use & Misuse 
41(10–12), 1395–1463.
Neuman, M.G., Schneider, M., Nanau, R.M. & Parry, C., 2012, ‘Alcohol consumption, 
progression of disease and other comorbidities, and responses to antiretroviral 
medication in people living with HIV’, AIDS Research and Treatment 2012, 14 
pages. http://dx.doi.org/10.1080/10826080600846235
National Institute on Alcohol Abuse and Alcoholism, 2012a, Moderate & binge 
drinking, viewed 23 March 2012, from http://www.niaaa.nih.gov/alcohol-health/
overview-alcohol-consumption/moderate-binge-drinking 
National Institute on Alcohol Abuse and Alcoholism, 2012b, Five Year Strategic Plan 
FY07-11. Alcohol across the lifespan, viewed 23 March 2012, from http://pubs.
niaaa.nih.gov/publications/StrategicPlan/NIAAASTRATEGICPLAN.htm 
Nyasulu, J.C., Muchiri, E., Mazwi, S.L. & Ratshefola, M., 2012, ‘NIMART rollout to 
primary healthcare facilities increases access to antiretrovirals in Johannesburg: 
An interrupted time series analysis’, South African Medical Journal 103(4), 
232–236.
Pandrea, I., Happel, K.I., Amedee, A.M., Bagby, G.J. & Nelson, S., 2010, ‘Alcohol’s role 
in HIV transmission and disease progression’, Alcohol Research & Health 33(3), 
203–218.
Papas, R.K., Sidle, J.E., Martino, S., Baliddawa, J.B., Songole, R., Omolo, O.E. et al., 
2010, ‘Systematic cultural adaptation of cognitive-behavioral therapy to reduce 
alcohol use among HIV-infected outpatients in western Kenya’, AIDS and Behavior 
14(3), 669–678. http://dx.doi.org/10.1007/s10461-009-9647-6
Parliamentary Monitoring Group, 2012, Health: Minister’s Budget Vote Speech, 
viewed 06 March 2012, from http://www.pmg.org.za/briefing/20120424-
minister-health-mr-aaron-motsoaledi-budget-vote-speech-201213 
Parry, C.D.H., 2010, ‘Alcohol policy in South Africa: A review of policy development 
processes between 1994 and 2009’, Addiction 105(8), 1340–1345.
Original Research
doi:10.4102/curationis.v37i1.1137http://www.curationis.org.za
Page 8 of 8
Parry, C.D.H., Rehm, J. & Morojele, N., 2010, ‘Is there a causal relationship between 
alcohol and HIV? Implications for policy, practice and future research’, African 
Journal of Drug and Alcohol Studies 9(2), 81–91. http://dx.doi.org/10.1111/
j.1360-0443.2010.03003.x
Potochnic, M.A., 2002, Cocktails and party favors, viewed 14 March 2012, from http://
www.thebody.com/content/art1891.html 
Pujol, G., 2003, Risky cocktails. Interactions between street drugs and HIV medications, 
viewed 12 April 2012, from http://www.thebody.com/content/art32513.html 
Rehm, J., Shield, K.D., Joharchi, N. & Shuper, P.A., 2012, ‘Alcohol consumption and the 
intention to engage in unprotected sex: Systematic review and meta-analysis of 
experimental studies’, Addiction 107(1), 51–59.
Rossiter, D. (ed.), 2012, The South African Medicines Formulary, viewed 05 June 2014, 
from http://www.hst.org.za/links/south-african-medicines-formulary
Sankar, A., Wunderlich, T., Neufeld, S. & Luborsky, M., 2007, ‘Sero-positive African 
Americans’ beliefs about alcohol and their impact on anti-retroviral adherence’, 
AIDS and Behavior 11(2), 195–203. http://dx.doi.org/10.1007/s10461-006-9144-0
Sanne, I., Orrell, C., Fox, M., Conradie, F., Ive, P., Zeinecker, J. et al., 2010, ‘Nurse 
management is not inferior to doctor management of ARV patients: The 
CIPRA South Africa randomised trial’, Lancet 376(9734), 33–40. http://dx.doi.
org/10.1016/S0140-6736(10)60894-X
Schneider, M., Norman, R., Parry, C., Bradshaw, D. & Plüddemann, A., 2007, ‘Estimating 
the burden of disease attributable to alcohol use in South Africa in 2000’, South 
African Medical Journal 97(8 Pt 2), 664–672.
Shisana, O., Rehle, T., Simbayi, L., Zuma, K., Jooste, S., Pillay-van-Wyk, V. et al., 2009, 
South African national HIV prevalence, incidence, behaviour and communication 
survey 2008: A turning tide among teenagers?, HSRC Press, Cape Town.
Shuper, P.A., Neuman, M., Kanteres, F., Baliunas, D., Joharchi, N. & Rehm, J., 2010, 
‘Causal considerations on alcohol and HIV/AIDS – a systematic review’, Alcohol 
and Alcoholism 45(2), 159–166. http://dx.doi.org/10.1093/alcalc/agp091
Simbayi, L.C., Kalichman, S.C., Jooste, S., Mathiti, V., Cain, D. & Cherry, C., 2004, 
‘Alcohol use and sexual risks for HIV infection among men and women receiving 
sexually transmitted infection clinic services in Cape Town, South Africa’, Journal 
of Studies on Alcohol 65(4), 434–442.
Strauss, S.M., Tiburcio, N.J., Munoz-Plaza, C., Gwadz, M., Lunievicz, J., Osborne, A. 
et al., 2009, ‘HIV care providers’ implementation of routine alcohol reduction 
support for their patients’, AIDS Patient Care and STDs 23(3), 211–218. http://
dx.doi.org/10.1089/apc.2008.0008
Szabo, G. & Mandrekar, P., 2010, ‘Focus on: Alcohol and the liver’, viewed 10 April 
2012, from http://pubs.niaaa.nih.gov/publications/arh40/87-96.htm 
The Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012, HIV and AIDS 
estimates, viewed 10 September 2013, from http://www.unaids.org/en/
regionscountries/countries/southafrica/ 
Wechsberg, W.M., Luseno, W.K., Karg, R.S., Young, S., Rodman, N., Myers, B. et al., 
2008, ‘Alcohol, cannabis, and methamphetamine use and other risk behaviours 
among Black and Coloured South African women: a small randomized trial in the 
Western Cape’, International Journal on Drug Policy 19(2), 130–139. http://dx.doi.
org/10.1016/j.drugpo.2007.11.018
World Health Organization, 2011, Global Status Report on Alcohol and Health 2011, 
viewed 25 March 2012, from http://www.who.int/substance_abuse/publications/
global_alcohol_report/en/index.html [now links to 2014 update].
Wyles, D.L. & Gerber, J.G., 2005, ‘Antiretroviral drug pharmacokinetics in hepatitis 
with hepatic dysfunction’, Clinical Infectious Diseases 40(1), 174–181.
